Immune checkpoint inhibitors, especially anti-PD-1 (programmed death protein 1) antibodies, target the dysfunctional immune system and induce CD8-positive T cells to kill tumor cells, completely altering the treatment of various cancers, including advanced melanoma. This evidence concerns the gene CD8A and cancer.